Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.

Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K. · 2017

Read Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. by Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5412427.txt.

Introduction

Reiter and co-authors review evidence that melatonin fights cancer at every stage. Their review appeared in the International Journal of Molecular Sciences. Melatonin is the body's night hormone. Lab studies credit it with many anti-cancer acts. It guards DNA from radical damage at initiation. It slows growth signals during progression. It also blocks steps that seed metastasis. The sheer number of actions puzzles the authors. They suspect one deeper action sits beneath them all.

Some effects run through membrane receptors. Others act directly inside cells. Breast cancer drew most early study. Many other cancer types now show sensitivity too. Melatonin can sharpen standard drug effects. It can even restore response in resistant tumors. It limits cancer cells entering blood vessels. It also cuts the toxic side effects of chemotherapy. The authors urge clinical use of these gains. Patient wellbeing alone would justify co-treatment, they argue.

Catalog record

CREATORReiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE174 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5412427

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis By Russel J. Reiter, Sergio A. Rosales-Corral, Dun-Xian Tan, Dario Acuna-Castroviejo, Lilan Qin, Shun-Fa Yang, Kexin Xu, Andrzej Slominski Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18040843 ABSTRACT There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases. In many cases, the molecular mechanisms underpinning these inhibitory actions have been proposed. What is rather perplexing, however, is the large number of processes by which melatonin reportedly restrains cancer development and growth. These diverse actions suggest that what is being observed are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed. Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed molecule. While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin. There are several facets of this research which could have immediate applications at the clinical level. Many studies have shown that melatonin’s co-administration improves the sensitivity of cancers to inhibition by conventional drugs. Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies. Melatonin also inhibits molecular processes associated with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites. This is of particular importance since cancer metastasis often significantly contributes to death of the patient. Another area that deserves additional consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy. Although this information has been available for more than a decade, it has not been adequately exploited at the clinical level. Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the physical wellbeing of the patients. The experimental findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients. 1. INTRODUCTION In 2004, a brief commentary was published related to the then-explored mechanisms by which melatonin modulates cancer initiation and progression [1]. In that summary, several processes by which melatonin may protect against cancer risk were acknowledged. The first of these related to cancer initiation where melatonin, because of its radical scavenging actions [2,3,4,5,6], prevents damage to nuclear DNA [7,8,9,10] that results when it encounters reactive oxygen or nitrogen species [11,12,13]. DNA mutilated by any means can undergo mutation and proceed to cancer [14,15]; such damage persistently occurs, and if it goes unrepaired, it continues to accumulate throughout a life time and is likely a primary cause of cancer in the elderly [16]. At the time that brief article was written, melatonin had been also reported to employ several means to restrain cancer promotion. For example, Blask et al. [17] had found that, via processes involving one of the two known classic membrane receptors (MT1) [18,19], melatonin limited the cellular uptake of a growth-promoting fatty acid, i.e., linoleic acid (LA). After its entrance into the cell, LA is converted to 13-hydroxyoctadecadienoic acid (13-HODE) which causes a series of intracellular events that culminate in cancer cell proliferation. Some of these events involve epithelial growth factor (EGF), the phosphorylation and stimulation of downstream signaling molecules, and the mitogen-activated kinases, mitogen-activated protein kinase kinase (MEK) and Extracellular signal-regulated kinase (ERK) 1 and 2. These findings attracted interest since LA, an n-6 fat, is in much higher concentrations in modern-day diets compared to that of our ancestors and the incidence of certain cancer types is increasing in areas of the world where n-6 fats are disproportionally-elevated in the diet [20,21]. Blask et al. [22] also mentioned that dietary melatonin, which had been identified in edible foods roughly a decade earlier [23,24], may be a factor in the reduction of cancer risk. In addition to its ability to modify tumor growth by reducing LA uptake and metabolism, by 2004, it had also been found that melatonin inhibits telomerase activity and restrains the growth of MCF-7 human breast cancer xenografts growing in immunocompromised mice [25]. This enzyme is known to be essential for the synthesis of specialized ribonuclear proteins (the telomeres) that extend the ends of linear eukaryotic chromosomes. These molecular extensions are key for stabilizing chromosomal structure [26,27] and, as they shorten with each cell division as it occurs in normal cells [28,29], chromosomal structure is weakened leading to genetic instability and cellular aging. On the contrary, the usual upregulation of telomerase activity in cancer cells allows them to maintain DNA stability and contributes to their immortalization even though they undergo frequent mitoses. Thus, the observations that melatonin repressed telomerase activity in breast cancer cells has implications for the inhibition of this common cancer type. The antiestrogenic action of melatonin could also enhance the ability of the indole to limit the proliferation of hormone-sensitive breast cancer. This action had been documented in experiments that used human breast cancer cells that possess the estrogen receptor α (ERα) and involved the MT1 membrane receptor and possibly also a nuclear binding site (RZRα) [30,31]. This effect of melatonin as an oncostatic agent generally appeared less robust than that resulting from a reduction in LA uptake, but across studies it was highly reproducible. Finally, more indirect evidence identified yet another mechanism that could contribute to melatonin’s capacity to inhibit cancer growth. Kilic and coworkers [32], in a publication not involving cancer, had shown that melatonin markedly inhibits the levels of endothelin-1 (ET-1) in the brain of patients suffering from a stroke. ET-1, an important agent in promoting angiogenesis, had been implicated in the control of cancer enlargement [33]. ET-1 is often elevated in the plasma of patients with cancer [34]; it not only promotes the ingrowth of blood vessels, a process critical for cancer cells to obtain the required nutrients for rapid growth and for metastasis, ET-1 also protects cancer cells from undergoing apoptosis. Based on the findings summarized above, at the conclusion of the 2004 commentary [1], use of melatonin was urged in clinical trials in cancer patients. At that time, there had been some uncontrolled, partially successful trials by Lissoni’s group [35,36,37] which suggested that melatonin would be useful in reducing cancer growth and in improving patient wellbeing but the data were highly fragmentary and inconclusive. In the interval between 2004 and the present, this field of research has expanded rapidly and the data today are essentially overwhelmingly convincing that melatonin has significant utility as an agent that negatively impacts multiple features of experimental cancers [38,39,40]. These data are reviewed herein and, again, the rationale for performing clinical trials with melatonin as a cancer therapy is patently obvious. This review does not evaluate all of the published reports that have confirmed melatonin’s capacity as an anticancer agent. Rather, papers were selected to illustrate the variety of tumor types modulated by melatonin and especially

Read the complete text